Study of DB8 imaging in estrogen receptor positive and negative breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a special imaging agent called DB8 to see how it builds up in breast tumors. It compares results between women with estrogen receptor-positive and estrogen receptor-negative cancers to help improve detection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- You must have breast cancer and know your estrogen receptor status from a previous biopsy.
- Your blood counts, liver, and kidney function must be within certain limits (your doctor can check this).
- If you could become pregnant, you must have a negative pregnancy test and use birth control for at least 30 days after the study ends.
- You cannot be currently receiving chemotherapy or targeted therapy.
- You cannot have another type of cancer, an active autoimmune disease, or a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that may help doctors see breast cancer more clearly. The test uses a radioactive tracer that attaches to a protein on cancer cells, which could help plan your treatment.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
This trial tests a new imaging agent (99mTc-MY6349) to see if it can detect Trop2, a protein found on some breast cancer cells. It may help doctors better see and understand triple-negative breast cancer that has spread.
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.